back to US directory
us clinical guidance

Semaglutide (Wegovy) for chronic weight management

Current US Wegovy indications, formulation-specific initiation, monitoring, contraindications and long-term treatment review.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Patients being considered for FDA-approved Wegovy injection or tablets. The 2026 label distinguishes formulation, age and indications and also includes cardiovascular-risk and selected MASH indications; this page focuses on chronic weight management and does not equate Ozempic, Rybelsus or compounded semaglutide with Wegovy.
sources for this section:FDA Wegovy label

The Bottom Line

  • Use Wegovy with a reduced-calorie diet and increased physical activity for the exact age, BMI and comorbidity population in the current FDA label; verify whether the intended formulation and indication match.
  • Follow the formulation-specific initiation and escalation schedule to improve gastrointestinal tolerability, and do not improvise dose conversion between injection, tablets or another semaglutide product.
  • Do not combine Wegovy with another semaglutide-containing product or another GLP-1 receptor agonist; reconcile diabetes and weight prescriptions across clinicians and pharmacies.
  • Evaluate response through weight and complication outcomes, tolerability, nutrition, function, adherence and patient goals; long-term therapy may be needed and stopping commonly permits regain.
  • For an adult with established cardiovascular disease and overweight or obesity, recognize the separate FDA indication to reduce major adverse cardiovascular events without assuming every person with obesity has that indication.
sources for this section:FDA Wegovy label

Practical clinical workflow

1
Confirm labeled eligibility and goals, review prior treatment, current GLP-1 products, diabetes medicines, retinopathy, pancreatitis, gallbladder disease, gastroparesis, kidney status, pregnancy plans and upcoming procedures.
2
Record baseline weight and complication measures, choose injection or tablet intentionally, teach administration and missed-dose instructions from the current label, and arrange titration follow-up.
3
During escalation, assess nausea, vomiting, bowel symptoms, hydration, glucose when diabetes is present and the effect on other oral or glucose-lowering medicines.
4
At maintenance, review health benefit, adverse effects, medication access and whether nutrition, resistance activity and behavioral support protect function and treatment persistence.
5
Coordinate peri-procedural planning with anesthesia because delayed gastric emptying and reported pulmonary aspiration require individualized risk assessment rather than a generic automatic hold.
sources for this section:FDA Wegovy label

Safety boundaries and escalation

  • Wegovy has a boxed warning about thyroid C-cell tumors in rodents and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2, and with serious hypersensitivity to semaglutide.
  • Stop and assess suspected pancreatitis; investigate gallbladder symptoms, monitor kidney function when gastrointestinal losses can cause volume depletion, and avoid use in severe gastroparesis under current labeling.
  • Reduce and monitor insulin or insulin-secretagogue therapy when appropriate to limit hypoglycemia, and monitor people with diabetic retinopathy for progression during rapid glucose improvement.
  • Discontinue for recognized pregnancy and use the label鈥檚 preconception interval; product form and current labeling also affect lactation and oral-drug counseling.
sources for this section:FDA Wegovy label

Localization

Insurer criteria can be narrower than FDA eligibility and must not be presented as clinical evidence. Use only FDA-approved presentations from a lawful supply chain.
sources for this section:FDA Wegovy label

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Food and Drug AdministrationWEGOVY (semaglutide), current US prescribing informationDrugs@FDA application 215256; current label checked 2026-08-20 路 accessed 2026-08-20
    view source
  2. American Gastroenterological Association Clinical Guidelines CommitteeAGA Clinical Practice Guideline on Pharmacological Interventions for Adults With ObesityDOI 10.1053/j.gastro.2022.08.045 路 published 2022-11-01 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.